Literature DB >> 17348123

Metabolic syndrome: why the controversy?

Richard E Pratley1.   

Abstract

As originally conceived, the metabolic syndrome defined a clustering of cardiovascular disease risk factors with insulin resistance as the common, underlying pathophysiologic determinant. The definition of the syndrome has evolved since then, with several groups proposing somewhat differing definitions. Partly, this has been motivated by efforts to make the syndrome a clinically useful entity. However, recent articles have called the clinical use of the metabolic syndrome into question. In this review, some of these concerns and counterarguments for the continued use of the metabolic syndrome are reviewed.

Entities:  

Mesh:

Year:  2007        PMID: 17348123     DOI: 10.1007/s11892-007-0010-x

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   5.430


  23 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 2.  The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications.

Authors:  E Eschwège
Journal:  Diabetes Metab       Date:  2003-09       Impact factor: 6.041

3.  The metabolic syndrome--a new worldwide definition.

Authors:  K George M M Alberti; Paul Zimmet; Jonathan Shaw
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

Review 4.  The metabolic syndrome: a call to action.

Authors:  Antonio M Gotto; George L Blackburn; George E Dailey; Alan J Garber; Scott M Grundy; Burton E Sobel; Matthew R Weir
Journal:  Coron Artery Dis       Date:  2006-02       Impact factor: 1.439

Review 5.  Acquired immune deficiency syndrome.

Authors:  A P Waterson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-05

6.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

Authors:  H C Gerstein; S Yusuf; J Bosch; J Pogue; P Sheridan; N Dinccag; M Hanefeld; B Hoogwerf; M Laakso; V Mohan; J Shaw; B Zinman; R R Holman
Journal:  Lancet       Date:  2006-09-23       Impact factor: 79.321

7.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

8.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

9.  An epidemiological test of the hyperinsulinemia-hypertension hypothesis.

Authors:  D C Muller; D Elahi; R E Pratley; J D Tobin; R Andres
Journal:  J Clin Endocrinol Metab       Date:  1993-03       Impact factor: 5.958

10.  Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators.

Authors:  G Howard; D H O'Leary; D Zaccaro; S Haffner; M Rewers; R Hamman; J V Selby; M F Saad; P Savage; R Bergman
Journal:  Circulation       Date:  1996-05-15       Impact factor: 29.690

View more
  5 in total

1.  The metabolic syndrome: what's in a name?

Authors:  Glenn Matfin
Journal:  Ther Adv Endocrinol Metab       Date:  2010-04       Impact factor: 3.565

2.  Metabolic syndrome and incident peripheral artery disease - the Multi-Ethnic Study of Atherosclerosis.

Authors:  Himabindu Vidula; Kiang Liu; Michael H Criqui; Moyses Szklo; Matthew Allison; Christopher Sibley; Pamela Ouyang; Russell P Tracy; Cheeling Chan; Mary M McDermott
Journal:  Atherosclerosis       Date:  2015-09-03       Impact factor: 5.162

Review 3.  Alternative and complementary treatments for metabolic syndrome.

Authors:  Mariya Power; Richard Pratley
Journal:  Curr Diab Rep       Date:  2011-06       Impact factor: 4.810

Review 4.  Challenges in developing drugs for the metabolic syndrome.

Authors:  Glenn Matfin
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

Review 5.  A review of the epidemiology of oral and pharyngeal carcinoma: update.

Authors:  Daniel M Saman
Journal:  Head Neck Oncol       Date:  2012-01-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.